ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/019/SRR30660819/SRR30660819_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/013/SRR30660813/SRR30660813_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/015/SRR30660815/SRR30660815_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/021/SRR30660821/SRR30660821_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/017/SRR30660817/SRR30660817_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/015/SRR30660815/SRR30660815_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/018/SRR30660818/SRR30660818_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/021/SRR30660821/SRR30660821_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/018/SRR30660818/SRR30660818_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/016/SRR30660816/SRR30660816_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/012/SRR30660812/SRR30660812_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/014/SRR30660814/SRR30660814_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/012/SRR30660812/SRR30660812_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/020/SRR30660820/SRR30660820_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/019/SRR30660819/SRR30660819_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/020/SRR30660820/SRR30660820_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/013/SRR30660813/SRR30660813_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/017/SRR30660817/SRR30660817_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/016/SRR30660816/SRR30660816_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR306/014/SRR30660814/SRR30660814_2.fastq.gzprimaryOK200GenomicsMayo Clinichttps://www.ebi.ac.uk/ena/browser/view/PRJNA1160863Noncanonical immunogenic peptides in ovarian cancer hints at their potential role in anti-tumor immunityENAfalseImmunogenic noncoding cryptic peptides dominate the antigenic landscape of ovarian cancer2025-01-172025-01-17PRJNA1160863